Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.
Read Full NewsPatients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.
Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.
Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.
1.
In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.
2.
Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.
3.
Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?
4.
Spicy Chip Death Lawsuit; Gen X and Cancer; Extreme U.S. Temperatures
5.
Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models
1.
Effective Management Strategies for Sickle Cell Crisis: Insights from Medical Experts
2.
Public Health Planning for Equitable Access to Advanced Hematology Services
3.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
4.
Comprehensive Applications in Hematology for Better Care
5.
Quality of Life Through Personalized Survivorship Navigation After Multimodal Cancer Therapy
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
3.
Understanding Anemia: Causes and Treatment
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge